Current concept of the diagnostics and treatment of vulvovaginal candidosis

Cover Page

Abstract


In spite of high prevalence of vulvovaginal candidosis (VVC), its diagnostics and treatment pose a serious problem. Factors such as accessibility of antimycotic drugs, their uncontrolled application by patients and absence of any appropriate laboratory diagnostics result in the growth of the incidence rate, in particular, of recurrent forms related to a steady growth in the number of fungi of clinical importance as well as strains resistant to antifungal drugs. Discussion and conclusion. Today the problem of the need to develop VVC prevention drugs is increasingly urgent because reduced immunity results in relapses of the disease. Clinical trials of drugs for immune system correction are ongoing, and some of them have reached Phase 2. Based on the present-day research data, it is possible to conclude that the key standards for VVC diagnostics and treatment are as follows: mandatory diagnostics with the use of microbiological tests to determine the sensitivity to antifungal medicines, in particular, in case of recurrent VVC, and collection of detailed medical history data and physical examination to determine the form and severity of the disease (acute, recurrent, complicated or uncomplicated) and treatment duration: 1-7 days for acute uncomplicated forms and 7-14 days for recurrent complicated forms. The specific drug and route of administration are to be selected based on the physician’s preferences, patient’s convenience and cost of the drug provided the drug sensitivity is determined by laboratory tests. The administration of probiotics for VVC prevention and treatment is disputable today.

YE. T. Malbakhova

Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: e.malbakhova@mail.ru

Russian Federation

V. G. Arzumanyan

Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru

Russian Federation

  1. Кисина В.И., Степанова Ж.В., Мирзабекова М.А., Курчавов В.А. Зависимость клинической картины кандидозного вульвовагинита от видового состава грибов Candida и эффективность флуконазола при первичной и рецидивирующей кандидаинфекции. Гинекология. Consilium Medicum 2000; 2 (6): 193-195
  2. Рахманова С.Н., Юцковский А.Д., Накорякова Л.Ф. Тихоокеанский медицинский журнал 2009; (1): 92-94
  3. Мальбахова Е.Т. и соавт. Вульвовагинальный кандидоз: видовое разнообразие и чувствительность к противогрибковым препаратам. Акушерство и гинекология 2009; (4); 44-46
  4. Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG. 2014 Jul 23. doi: 10.1111/14710528.12994. [Epub ahead of print] Patient Prefer Adherence. 2014; 8: 31-34.]
  5. Huan Yu Xie, Dan Feng, Dong Mei Wei,Hui Chen, Ling Mei, Xun Wang, Fang Fang Probiotics for vulvovaginal candidiasis in non-pregnant women Editorial Group: Cochrane Sexually Transmitted Infections Group Published Online: 30 APR 2013 doi: 10.1002/14651858.CD010496 Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
  6. Ilkit M., Guzel A.B. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: A mycological perspective. Critical Reviews in Microbiology 2011; 37 (3): 250-61
  7. Nurbhai M., Grimshaw J., Watson M., Bond C., Mollison J., Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database of Systematic Reviews 2007, Issue 4. [doi: 10.1002/14651858. CD002845.pub2]
  8. Omar A.A. Gram stain versus culture in the diagnosis of vulvovaginal candidiasis. Eastern Mediterranean Health Journal 2001; 7 (6): 925-34.
  9. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K. Jr, Calandra T.F., Edwards J.E. Jr, et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 2009; 48 (5): 503-35.
  10. Reef S.E., Levine W.C., McNeil M.M., et al. Treatment options for vulvovaginal candidiasis, 1993. Clin Infect Dis. 1995; 20 (Suppl 1): S80-S90. [PubMed].
  11. Watson M.C., Grimshaw J.M., Bond C.M., Mollison J., Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)Cochrane Database Syst Rev. 2001; 4: CD002845. [PubMed].
  12. Sobel J.D., Brooker D., Stein G.E. et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol. 1995; 172: 1263-1268. [PubMed].
  13. Sobel J.D., Faro S., Force R.W. et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998; 178: 203-211. [PubMed].
  14. Sobel J.D. Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis.Patient Prefer Adherence. 2014; 8: 31-34. Published online Dec 16, 201.

Views

Abstract - 60

PDF (Russian) - 16

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies